Tag: IL-23
Upadacitinib appears to be an efficacious therapy for moderately-to-severely ulcerative colitis
Guselkumab shows encouraging safety and efficacy in ulcerative colitis
Guselkumab maintenance therapy achieved high efficacy rates in Crohn’s disease
Mirikizumab efficacious for active ulcerative colitis
Risankizumab more efficacious in colonic than in ileal Crohn’s disease
Guselkumab plus golimumab promising combination for ulcerative colitis
Potential biomarker discovered for treatment response to ustekinumab
Explaining arthropathy development through IL-4 and IL-13 blockade
Patients on immunomodulators need 2 COVID-19 vaccinations before seroconversion
Selective IL-23 inhibition normalises gene expression in active PsA
Existing and upcoming small molecules in psoriasis
Risankizumab meets primary endpoints in maintenance study for CD patients
Psoriatic arthritis: Guidelines and best practice
Selective IL-23 blocker shows potential in psoriasis treatment
Sustained efficacy of mirikizumab in moderate-to-severe Crohn’s disease
Selective IL-23 blocker safe in elderly psoriasis patients
ECLIPSE trial: skin clearance independent of PsA status at baseline
Novel IL-23 blocker risankizumab highly effective and tolerable in psoriasis
Can gene expression help to pick the right biologic to treat psoriasis in cancer patients?
Lowest risk of infection after therapy with an IL-12/IL-23 blocker
Selective IL-23 blocker shows remarkable efficacy in patients with psoriatic arthritis
Phase 2 data shows benefit for mirikizumab in CD patients
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints
New targets and biologics for cutaneous lupus erythematosus
Novel selective IL-23 blocker highly effective over 2 years
Biologicals beyond TNF blockade
Registries – an important research tool in biologics
Advances in target-oriented therapy: psoriatic arthritis
